Anxious, Two Years in Recovery and on Buprenorphine: Treating Generalized Anxiety Without a Benzodiazepine, With Evidence on SSRIs, Buspirone and Hydroxyzine
[Student Name]
University of Phoenix
PMH/502: Neuropsychiatric Pharmacology
Week 6 Assignment
[Instructor Name]
[Date]
The patient is a composite written for a model paper.
Mr. N., a 36-year-old warehouse lead, has been in recovery from opioid use disorder for two years on buprenorphine-naloxone 16 mg daily. For the past six months, he has had constant worry about money, his job and his children, muscle tension, poor sleep and irritability. His GAD-7 score is 15. A coworker gave him alprazolam once and "it was the first time I felt calm," and he asks for a prescription. This paper explains my response.
Diagnosis
Half a year of worry that is out of proportion, difficult to switch off and spread across several parts of life, with restlessness, muscle tension, irritability and sleep disturbance, meets criteria for generalized anxiety disorder. I screen for depression, with a PHQ-9 of 9, and ask about any return to opioid or other substance use, which he denies; his urine test confirms only buprenorphine.
Why Not Alprazolam
The CDC clinical practice guideline for prescribing opioids advises clinicians to use particular caution and weigh risks when prescribing benzodiazepines with opioids, because the combination increases the risk of potentially fatal respiratory depression and overdose (Dowell et al., 2022). Buprenorphine has a ceiling on respiratory depression when used alone, but that protection is reduced with sedatives. Alprazolam also has a rapid onset and short half-life that promote misuse, and those risks are higher still for someone who has lived with an addiction before. The relief he felt from one dose is part of the concern.
The calm he felt from one borrowed pill is the reason, not the argument, for choosing something else.
What the Evidence Offers
Slee et al. (2019) conducted a network meta-analysis of pharmacological treatments for generalized anxiety disorder and ranked duloxetine, pregabalin, venlafaxine and escitalopram among the options that beat placebo while being reasonably well tolerated, supporting SSRIs and SNRIs as first-line treatments. Pregabalin, though effective, has misuse potential, especially with opioids, which argues against it for Mr. N.
Buspirone
Chessick et al. (2006), in a Cochrane review of 36 trials, found that azapirones, including buspirone, outperformed placebo for generalized anxiety, with roughly one extra responder for every four or five people treated, and appeared particularly useful in people who had not taken benzodiazepines; side effects were mild. Buspirone has no misuse potential or respiratory effects, making it suitable as an addition if an SSRI is not enough.
Hydroxyzine for Short-Term Relief
Guaiana et al. (2010), in a Cochrane review, found hydroxyzine more effective than placebo for generalized anxiety disorder, though evidence was limited, and noted sedation as a common side effect. Hydroxyzine, an antihistamine without misuse potential, can provide relief during the weeks before an SSRI takes effect.
The Plan
I start escitalopram 5 mg daily for one week, then 10 mg, and prescribe hydroxyzine 25 mg as needed for acute anxiety, up to three times a day, cautioning about sedation. If response is partial after eight weeks, I will increase escitalopram or add buspirone. I refer him for cognitive behavioral therapy, which has strong evidence for generalized anxiety disorder.
Coordination With His Buprenorphine Prescriber
With his consent, I inform his buprenorphine prescriber of the diagnosis and plan and check the prescription drug monitoring program, which shows no other controlled substances.
Addressing His Request Honestly
I tell Mr. N. directly why I will not prescribe alprazolam, acknowledge that his anxiety is real and severe and explain that the plan aims to give lasting relief without risking his recovery. He is disappointed but agrees, especially when I explain that hydroxyzine can help within the first week.
Why Not Gabapentin or Pregabalin
Gabapentinoids are sometimes suggested as benzodiazepine alternatives, but both can be misused, particularly by people using opioids, and combining them with opioids increases the risk of respiratory depression. For Mr. N., their risks mirror the benzodiazepine concern, so I avoid them.
How Long Before the SSRI Helps
Escitalopram typically takes two to six weeks to reduce anxiety, and some people feel more restless in the first days. Starting at 5 mg reduces this, and hydroxyzine bridges the gap. Setting expectations reduces the chance he stops early or seeks alprazolam elsewhere.
The Role of Therapy
Cognitive behavioral therapy teaches patients to identify and challenge worry, reduce avoidance and manage physical tension. For someone in recovery, it also builds coping skills that support sobriety. Many recovery programs offer it, and I refer him to one that coordinates with his buprenorphine clinic.
Stressors
Much of Mr. N.'s worry is about money and his children, real stressors. A social worker can help with financial counseling and childcare resources, which may reduce anxiety as much as medication.
Relapse Risk
Untreated anxiety is a known trigger for return to substance use. Treating it effectively, without adding a misusable drug, is part of protecting his recovery. I ask him to tell me or his buprenorphine prescriber if cravings increase.
What If He Obtains Benzodiazepines Anyway
I ask him directly not to use benzodiazepines from other sources and explain that combining them with buprenorphine, especially with alcohol, can stop breathing. I prescribe naloxone and teach his partner how to use it, as a safety measure.
Documentation
The note records the diagnosis, the reason for declining a benzodiazepine, the monitoring program check, the medications chosen and the coordination with his buprenorphine prescriber.
Why Honesty Matters
People in recovery often expect to be judged. Explaining my reasoning openly and taking his anxiety seriously keeps him engaged, which is itself protective.
Measuring Response
The GAD-7 score of 15 serves as a baseline. A reduction of at least 50% or a score below 5 would indicate good response. I will repeat it at each visit and adjust treatment if progress stalls.
Exercise
Regular aerobic exercise reduces anxiety symptoms and supports recovery. He enjoys basketball, and we set a goal of playing twice a week.
Caffeine and Energy Drinks
He drinks two energy drinks a day on long shifts. High caffeine intake worsens anxiety and sleep, and cutting down gradually can reduce symptoms without medication.
Follow-Up With His Recovery Team
I will send a brief update to his counselor after each medication change so his recovery team stays informed and can reinforce the same plan in counseling and group sessions.
Sleep
His insomnia is part of his anxiety. I recommend sleep hygiene and, if needed, cognitive behavioral therapy for insomnia, avoiding sedative-hypnotics that add risk with buprenorphine.
Follow-Up
I will see him in two weeks to review side effects, GAD-7 score and hydroxyzine use, and at six weeks for response.
Conclusion
Mr. N.'s generalized anxiety disorder is real and treatable, but alprazolam would add overdose and misuse risk to his buprenorphine treatment, as the CDC guideline warns. Evidence supports escitalopram as first-line, buspirone as a safe augmenting option and hydroxyzine for short-term relief, with cognitive behavioral therapy, together giving him relief without endangering his recovery.
References
Chessick, C. A., Allen, M. H., Thase, M. E., Batista Miralha da Cunha, A. A. B., Kapczinski, F., Silva de Lima, M., & dos Santos Souza, J. J. (2006). Azapirones for generalized anxiety disorder. Cochrane Database of Systematic Reviews, 2006(3), Article CD006115. https://doi.org/10.1002/14651858.CD006115
Dowell, D., Ragan, K. R., Jones, C. M., Baldwin, G. T., & Chou, R. (2022). CDC clinical practice guideline for prescribing opioids for pain: United States, 2022. MMWR Recommendations and Reports, 71(3), 1-95. https://doi.org/10.15585/mmwr.rr7103a1
Guaiana, G., Barbui, C., & Cipriani, A. (2010). Hydroxyzine for generalised anxiety disorder. Cochrane Database of Systematic Reviews, 2010(12), Article CD006815. https://doi.org/10.1002/14651858.CD006815.pub2
Slee, A., Nazareth, I., Bondaronek, P., Liu, Y., Cheng, Z., & Freemantle, N. (2019). Pharmacological treatments for generalised anxiety disorder: A systematic review and network meta-analysis. The Lancet, 393(10173), 768-777. https://doi.org/10.1016/S0140-6736(18)31793-8
How this PMH 502 Week 6 example is structured
The PMH/502 Week 6 work usually covers anxiolytics, hypnotics and benzodiazepine management. This paper shows why a common request is unsafe in a specific patient and how evidence guides the alternatives, including drugs used for faster relief. Students search this week as PMH 502 Week 6, PMH502 Wk 6 or PMH/502 Wk 6; all three are the same assignment.
PMH/502 Week 6 questions, answered
What does PMH/502 Week 6 usually ask for?
Many sections ask students to select anxiolytic or hypnotic treatment, including when to avoid benzodiazepines and how to use alternatives.
Why avoid benzodiazepines with buprenorphine?
Combining benzodiazepines with opioids, including buprenorphine, increases the risk of sedation, respiratory depression and overdose death, and benzodiazepines carry their own misuse potential in people with substance use disorders.
What treats generalized anxiety disorder without benzodiazepines?
SSRIs and SNRIs are first-line, buspirone is effective, particularly in people who have not used benzodiazepines, and hydroxyzine can be used for short-term relief.
Write yours, or have the desk draft it
This paper is an original model document written by our desk, not a submitted student paper and not an official University of Phoenix document. Read it for the moves, then write your own to the instructions in your classroom. If you want one built to your exact prompt and rubric, the first custom sample is free and arrives in 24 to 48 hours.